AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33307101 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal stimulation to the prefrontal cortex
Number of subjects: 150
Study 33307101 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal stimulation to the inferior parietal lobule
Number of subjects: 150
Study 33307101 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 150
Study 32206987 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhitong (XZT) 2700 mg daily
Number of subjects: 358
Study 32206987 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuezhikang (XZK) 1200 mg daily
Number of subjects: 358
Study 32206987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 358
Study 36030033 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy (BBT)
Number of subjects: 185
Study 34465810 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetically determined SMOX activity
Number of subjects: 0
Study 34465810 — intervention group
Group type: COMPARATOR
Intervention: SMOX locus (rs1741315)
Number of subjects: 0
Study 34465810 — intervention group
Group type: COMPARATOR
Intervention: GWAS of spermidine/spermine ratio
Number of subjects: 0
Study 34465810 — intervention group
Group type: COMPARATOR
Intervention: PheWAS of rs1741315
Number of subjects: 0
Study 33302685 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-α antagonist etanercept 25 mg subcutaneous injection two times a week for two weeks
Number of subjects: 1
Study 35881851 — intervention group
Group type: EXPERIMENTAL
Intervention: THC
Number of subjects: 18
Study 35881851 — intervention group
Group type: EXPERIMENTAL
Intervention: CBD
Number of subjects: 18
Study 35881851 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 35881851 — intervention group
Group type: EXPERIMENTAL
Intervention: THC+CBD
Number of subjects: 18
Study 34515985 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-102 (0.7% w/v cantharidin) with 6-h occlusion
Number of subjects: 0
Study 34515985 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-102 (0.7% w/v cantharidin) with 24-h occlusion
Number of subjects: 0
Study 34515985 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 32270482 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 551
Study 32270482 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 551
Study 35962657 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal high-flow therapy
Number of subjects: 202
Study 35962657 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no nasal high-flow therapy or supplemental oxygen)
Number of subjects: 202
Study 34225270 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic steroid‐cyclophosphamide regimen (modified Ponticelli protocol)
Number of subjects: 74
Study 34225270 — intervention group
Group type: COMPARATOR
Intervention: Rituximab (1 g × 2)
Number of subjects: 74
Study 34225270 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 74
Study 35322972 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal epidural steroid injection (CESI)
Number of subjects: 56
Study 35322972 — intervention group
Group type: EXPERIMENTAL
Intervention: Transforaminal epidural steroid injection (TFESI)
Number of subjects: 56
Study 32594305 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal omeprazole (1 mg/kg)
Number of subjects: 17
Study 32594305 — intervention group
Group type: COMPARATOR
Intervention: Oral omeprazole (1 mg/kg)
Number of subjects: 17
Study 32594305 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal omeprazole
Number of subjects: 17
Study 32594305 — intervention group
Group type: COMPARATOR
Intervention: Oral omeprazole
Number of subjects: 17
Study 32870520 — intervention group
Group type: EXPERIMENTAL
Intervention: Total diet replacement (825–853 kcal/day, 3–5 months, shakes/soups)
Number of subjects: 149
Study 32870520 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (kg)
Number of subjects: 149
Study 32870520 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life measures (anxiety/depression)
Number of subjects: 149
Study 32870520 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HbA1c
Number of subjects: 149
Study 32870520 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and sex
Number of subjects: 149
Study 32870520 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants prescription
Number of subjects: 149
Study 32870520 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss maintenance support (2 years)
Number of subjects: 149
Study 32546211 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 °C hypothermic perfusion
Number of subjects: 106
Study 32546211 — intervention group
Group type: COMPARATOR
Intervention: 24 °C control
Number of subjects: 106
Study 36064598 — intervention group
Group type: EXPERIMENTAL
Intervention: Active recharge burst spinal cord stimulation (SCS)
Number of subjects: 94
Study 36064598 — intervention group
Group type: COMPARATOR
Intervention: Passive recharge burst spinal cord stimulation (SCS)
Number of subjects: 94
Study 32298407 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice from a doctor or health professional to improve diet
Number of subjects: 193
Study 32298407 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice from a doctor or health professional to improve exercise
Number of subjects: 193
Study 32198596 — intervention group
Group type: EXPERIMENTAL
Intervention: MSC therapy (Men‐MSCs)
Number of subjects: 31
Study 32198596 — intervention group
Group type: COMPARATOR
Intervention: Routine ICSI
Number of subjects: 31
Study 34777570 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with repeated transcranial magnetic stimulation
Number of subjects: 0
Study 34777570 — intervention group
Group type: COMPARATOR
Intervention: Traditional paralysis treatment
Number of subjects: 0
Study 34777570 — intervention group
Group type: COMPARATOR
Intervention: Repeated transcranial magnetic stimulation alone
Number of subjects: 0
Study 32444033 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender herbal tea (2 g teabag, 2 times daily for 2 weeks)
Number of subjects: 60
Study 37608258 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage MRgRT in 5 fractions (32.5 Gy over 2 weeks)
Number of subjects: 136
Study 37608258 — intervention group
Group type: COMPARATOR
Intervention: Salvage MRgRT in 20 fractions (55 Gy over 4 weeks)
Number of subjects: 136
Study 37608258 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety endpoints (GI and GU symptoms)
Number of subjects: 136
Study 37608258 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy endpoints
Number of subjects: 136
Study 32579066 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrazole based sulfonamides; specific compounds include NMT106, NMT157, NMT187, NMT236; dosage and duration not specified.
Number of subjects: 0
Study 33801767 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flavanol cocoa (150 mg)
Number of subjects: 30
Study 33801767 — intervention group
Group type: COMPARATOR
Intervention: Low-flavanol cocoa (<4 mg (‐)‐epicatechin)
Number of subjects: 30
Study 32163799 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml of grape juice
Number of subjects: 103
Study 32163799 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g glucose
Number of subjects: 103
Study 32163799 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g maltodextrin
Number of subjects: 103
Study 32163799 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sugar administration)
Number of subjects: 103
Study 34864766 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic locomotor training (60-min sessions, 3× per week, over 24 wks)
Number of subjects: 16
Study 34864766 — intervention group
Group type: COMPARATOR
Intervention: Activity-based training (60-min sessions, 3× per week, over 24 wks)
Number of subjects: 16
Study 32828927 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual high-intensity intermittent aerobic exercise (vHIE) in first-person perspective (1PP)
Number of subjects: 45
Study 32828927 — intervention group
Group type: COMPARATOR
Intervention: Virtual high-intensity intermittent aerobic exercise (vHIE) in third-person perspective (3PP)
Number of subjects: 45
Study 35237336 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 90
Study 35237336 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 90
Study 35237336 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 90
Study 34049672 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 to 3 months of dual antiplatelet therapy (DAPT) followed by P2Y12 inhibitor monotherapy
Number of subjects: 18046
Study 34049672 — intervention group
Group type: COMPARATOR
Intervention: 12 months of dual antiplatelet therapy (DAPT)
Number of subjects: 18046
Study 32122921 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose cytarabine
Number of subjects: 348
Study 32122921 — intervention group
Group type: COMPARATOR
Intervention: Standard dose cytarabine
Number of subjects: 348
Study 32122921 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant genotype rs17202778 C/C
Number of subjects: 348
Study 33112481 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal REG1B concentration
Number of subjects: 694
Study 36208303 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Intervention (MB-SI)
Number of subjects: 20
Study 36208303 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 20
Study 36208303 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness-Based Intervention (MB-SI) and Treatment as Usual (TAU)
Number of subjects: 20
Study 34044838 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis group (standardized hypnotic message)
Number of subjects: 69
Study 34044838 — intervention group
Group type: COMPARATOR
Intervention: Standard group (no intervention)
Number of subjects: 69
Study 34044838 — intervention group
Group type: COMPARATOR
Intervention: Music group (relaxing music)
Number of subjects: 69
Study 32167593 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy for former smokers
Number of subjects: 330
Study 32167593 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy for current smokers
Number of subjects: 330
Study 32167593 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy for former smokers with ≤20 pack-years
Number of subjects: 330
Study 32167593 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard therapy for all patients
Number of subjects: 330
Study 35697146 — intervention group
Group type: EXPERIMENTAL
Intervention: bamlanivimab
Number of subjects: 1935
Study 35697146 — intervention group
Group type: EXPERIMENTAL
Intervention: bamlanivimab-etesevimab
Number of subjects: 1935
Study 35697146 — intervention group
Group type: COMPARATOR
Intervention: casirivimab-imdevimab
Number of subjects: 1935
Study 34492446 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of antibiotic therapy
Number of subjects: 45
Study 34492446 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days of antibiotic therapy
Number of subjects: 45
Study 34059425 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized intervention
Number of subjects: 32
Study 34059425 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 32
Study 32482611 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% aluminium zirconium tetrachlorohydrate antiperspirant solution (AZCH)
Number of subjects: 14
Study 32197030 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid anesthesia combined with propofol TCI (group T)
Number of subjects: 240
Study 32197030 — intervention group
Group type: EXPERIMENTAL
Intervention: General anesthesia (GA) (group G)
Number of subjects: 240
Study 32197030 — intervention group
Group type: COMPARATOR
Intervention: Combined spinal-epidural anesthesia (CSEA) (group C)
Number of subjects: 240
Study 37183134 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy
Number of subjects: 69
Study 37183134 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 69
Study 37183134 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy in stoma patients
Number of subjects: 69
Study 37183134 — intervention group
Group type: COMPARATOR
Intervention: Standard care in stoma patients
Number of subjects: 69
Study 33919059 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind&Life intervention (ACT and mindfulness-based intervention plus TAU)
Number of subjects: 110
Study 33919059 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 110
Study 32194443 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine (1.5-6 mg)
Number of subjects: 66
Study 32194443 — intervention group
Group type: EXPERIMENTAL
Intervention: Cariprazine
Number of subjects: 66
Study 35050952 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day fasting (ADF)
Number of subjects: 101
Study 35050952 — intervention group
Group type: EXPERIMENTAL
Intervention: 16/8 time-restricted fasting (16/8 TRF)
Number of subjects: 101
Study 35050952 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 101
Study 33252552 — intervention group
Group type: EXPERIMENTAL
Intervention: Large head THA (Group A)
Number of subjects: 165
Study 33252552 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual mobility cup designs (Group B)
Number of subjects: 165
Study 33142503 — intervention group
Group type: EXPERIMENTAL
Intervention: L-DNJ (0.05 mg/g)
Number of subjects: 128
Study 33142503 — intervention group
Group type: EXPERIMENTAL
Intervention: M-DNJ (0.1 mg/g)
Number of subjects: 128
Study 33142503 — intervention group
Group type: EXPERIMENTAL
Intervention: H-DNJ (0.15 mg/g)
Number of subjects: 128
Study 33142503 — intervention group
Group type: COMPARATOR
Intervention: Control (ordinary diet without DNJ)
Number of subjects: 128
Study 33935111 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrolysin plus routine intervention program
Number of subjects: 0
Study 33935111 — intervention group
Group type: COMPARATOR
Intervention: Routine intervention program alone
Number of subjects: 0
Study 36433591 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (5 IU intravenously)
Number of subjects: 64
Study 36433591 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin (100 μg intramuscularly)
Number of subjects: 64
Study 33225442 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic assisted gait training (RAGT) combined with locomotor training (LT)
Number of subjects: 40
Study 33225442 — intervention group
Group type: COMPARATOR
Intervention: Locomotor training (LT) alone
Number of subjects: 40
Study 35245895 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesio Taping (KT)
Number of subjects: 51
Study 35245895 — intervention group
Group type: COMPARATOR
Intervention: KT-placebo
Number of subjects: 51
Study 35245895 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 51
Study 35245895 — intervention group
Group type: COMPARATOR
Intervention: All groups (KT, KT-placebo, No-treatment control)
Number of subjects: 51
Study 32371705 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.73% lidocaine carbonate (Group D)
Number of subjects: 80
Study 32371705 — intervention group
Group type: COMPARATOR
Intervention: Air (Group A)
Number of subjects: 80
Study 32371705 — intervention group
Group type: COMPARATOR
Intervention: Double distilled water (Group B)
Number of subjects: 80
Study 32371705 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine hydrochloride (Group C)
Number of subjects: 80
Study 34928693 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behavior therapy
Number of subjects: 156
Study 34928693 — intervention group
Group type: COMPARATOR
Intervention: General psychiatric management
Number of subjects: 156
Study 32244028 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengzhan Shengmai (DZSM) capsules
Number of subjects: 82
Study 32244028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 35613725 — intervention group
Group type: EXPERIMENTAL
Intervention: Eldecalcitol 0.75 μg per day (n=630)
Number of subjects: 1256
Study 35613725 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=626)
Number of subjects: 1256
Study 34988058 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital intervention for medication adherence
Number of subjects: 57
Study 34988058 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored intervention content and reporting on medication taking
Number of subjects: 57
Study 32842644 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-pyramid resistance training (NPR), 3 sets of 12/10/8 repetitions, 3x/week for 8 weeks
Number of subjects: 59
Study 32842644 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide-pyramid resistance training (WPR), 3 sets of 15/10/5 repetitions, 3x/week for 8 weeks
Number of subjects: 59
Study 32842644 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control (CON)
Number of subjects: 59
Study 34841615 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 515
Study 34841615 — intervention group
Group type: COMPARATOR
Intervention: Control (no spironolactone)
Number of subjects: 515
Study 34735643 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality intervention
Number of subjects: 60
Study 34735643 — intervention group
Group type: COMPARATOR
Intervention: Hospital routine care (control)
Number of subjects: 60
Study 35597311 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal tube (LT)
Number of subjects: 1000
Study 35597311 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal intubation (ETI)
Number of subjects: 1000
Study 33112184 — intervention group
Group type: EXPERIMENTAL
Intervention: KdD70 (once-weekly carfilzomib 70 mg/m2, dexamethasone, and daratumumab)
Number of subjects: 0
Study 33112184 — intervention group
Group type: COMPARATOR
Intervention: KdD56 (twice-weekly carfilzomib 56 mg/m2, dexamethasone, and daratumumab)
Number of subjects: 0
Study 33278330 — intervention group
Group type: COMPARATOR
Intervention: Single ascending dose (SAD) of vixotrigine
Number of subjects: 81
Study 33278330 — intervention group
Group type: COMPARATOR
Intervention: Multiple ascending dose (MAD) of vixotrigine (450 mg twice daily)
Number of subjects: 81
Study 32596729 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplement (90 mmol/day)
Number of subjects: 25
Study 36068547 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian platform trial design with beta-binomial model for binary outcomes
Number of subjects: 0
Study 36068547 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-adaptive randomization (RAR) schemes
Number of subjects: 0
Study 36068547 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical modeling of subgroups
Number of subjects: 0
Study 36068547 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment for potential drift over time
Number of subjects: 0
Study 34160347 — intervention group
Group type: EXPERIMENTAL
Intervention: TetraStim (four consecutive minimal COS)
Number of subjects: 128
Study 33066857 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical moxibustion (EM)
Number of subjects: 138
Study 33066857 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional indirect moxibustion (TIM)
Number of subjects: 138
Study 33066857 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 138
Study 34173940 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcifediol
Number of subjects: 284
Study 34173940 — intervention group
Group type: COMPARATOR
Intervention: Control (no additional therapy)
Number of subjects: 284
Study 34684368 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg·kg−1)
Number of subjects: 30
Study 34684368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 34684368 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training intervention
Number of subjects: 30
Study 32516494 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison chart format
Number of subjects: 301
Study 32516494 — intervention group
Group type: COMPARATOR
Intervention: Sequential text descriptions
Number of subjects: 301
Study 32516494 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formats
Number of subjects: 301
Study 34246515 — intervention group
Group type: EXPERIMENTAL
Intervention: BCT + IBT
Number of subjects: 75
Study 34246515 — intervention group
Group type: COMPARATOR
Intervention: IBT
Number of subjects: 75
Study 32473678 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib with obinutuzumab
Number of subjects: 0
Study 32473678 — intervention group
Group type: EXPERIMENTAL
Intervention: Acalabrutinib without obinutuzumab
Number of subjects: 0
Study 32473678 — intervention group
Group type: COMPARATOR
Intervention: Chlorambucil and obinutuzumab
Number of subjects: 0
Study 2012036615 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan, 40 mg daily
Number of subjects: 4447
Study 2012036615 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4447
Study 35630559 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mmol salicylic acid with full irrigation
Number of subjects: 0
Study 35630559 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mmol salicylic acid in dryland
Number of subjects: 0
Study 35630559 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mmol salicylic acid with 50% irrigation
Number of subjects: 0
Study 35630559 — intervention group
Group type: COMPARATOR
Intervention: 0 mmol salicylic acid with non-irrigation
Number of subjects: 0
Study 32903125 — intervention group
Group type: EXPERIMENTAL
Intervention: Trapeziectomy alone
Number of subjects: 28
Study 32903125 — intervention group
Group type: COMPARATOR
Intervention: Trapeziectomy with LRTI
Number of subjects: 28
Study 32903125 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study 33436851 — intervention group
Group type: EXPERIMENTAL
Intervention: Domain randomization strategy applied to deep learning models for bird detection
Number of subjects: 0
Study 33436851 — intervention group
Group type: COMPARATOR
Intervention: Conventional manual observations
Number of subjects: 0
Study 33436851 — intervention group
Group type: COMPARATOR
Intervention: Long-term bird surveys using intensive monitoring
Number of subjects: 0
Study 34035100 — intervention group
Group type: EXPERIMENTAL
Intervention: Butylphthalide (NBP)
Number of subjects: 1200
Study 34035100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200